Inceptua Group Selected to Manage TikoMed’s Named Patient Program for Investigational Therapy ILB® in Amyotrophic Lateral Sclerosis (ALS)
Inceptua Group (Inceptua) and TikoMed AB (TikoMed) have announced the launch of a Named Patient Programme for TikoMed’s investigational drug, ILB®, for eligible pati...



